Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
| Autor: | Marta Kucharska-Lipowska, Ewa Gruszka, Alina Kułakowska, Adam Perenc, Beata Lech, Monika Marona, Przemysław Puz, Karolina Kania, Beata Zwiernik, Agnieszka Slowik, Joanna Tarasiuk, Olga Zajkowska, Katarzyna Kubicka-Bączyk, Anna Pokryszko-Dragan, Natalia Niedziela, Małgorzata Popiel, Sławomir Wawrzyniak, Sławomir Budrewicz, Bożena Lewańczyk, Monika Chorąży, Monika Adamczyk-Sowa, Marcin Wnuk, Agata Czarnowska, Paweł Warmus, Anetta Lasek-Bal, Katarzyna Maciejowska, Waldemar Brola, Anna Michałowska, Alicja Kalinowska-Łyszczarz, Anna Niezgodzińska-Maciejek, Marta Białek, Jacek Zwiernik, Krzysztof Nosek, Halina Bartosik-Psujek, Katarzyna Kapica-Topczewska, Anna Mirończuk, Jan Kochanowicz, Klaudia Nowak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Demographics business.industry SARS-CoV-2 Multiple sclerosis Maximum likelihood Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 General Medicine Odds ratio medicine.disease Logistic regression multiple sclerosis Article residual symptoms disease modifying therapies Internal medicine medicine Medicine business |
| Zdroj: | Journal of Clinical Medicine, Vol 10, Iss 5225, p 5225 (2021) Journal of Clinical Medicine Volume 10 Issue 22 |
| ISSN: | 2077-0383 |
| Popis: | (1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|